Login Register Cart 0
Generic placeholder image

Central Nervous System Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5249
ISSN (Online): 1875-6166

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Molecular Pathway, Epidemiological Data and Treatment Strategies of Fungal Infection (Mycoses): A Comprehensive Review

Author(s): Namrata Singh, Vibha Kumari, Karan Agrawal and Mayank Kulshreshtha*

Volume 24, Issue 1, 2024

Published on: 16 January, 2024

Page: [68 - 81] Pages: 14

DOI: 10.2174/0118715249274215231205062701

Price: $65

Abstract

The recent increase in fungal infections is a health crisis. This surge is directly tied to the increase in immunocompromised people caused by changes in medical practice, such as the use of harsh chemotherapy and immunosuppressive medicines. Immunosuppressive disorders such as HIV have exacerbated the situation dramatically. Subcutaneous or superficial fungal infections can harm the skin, keratinous tissues, and mucous membranes. This category includes some of the most common skin disorders that impact millions of people worldwide. Despite the fact that they are seldom fatal, they can have a catastrophic impact on a person's quality of life and, in rare situations, spread to other people or become obtrusive. The majority of fungal infections under the skin and on the surface are simply and quickly cured. An opportunistic organism that preys on a weak host or a natural intruder can both result in systemic fungal infections. Furthermore, it might be exceedingly lethal and dangerous to one's life. Dimorphic fungi may pose a hazard to healthy populations that are not exposed to endemic fungi. Increased surveillance, the availability of quick, noninvasive diagnostic tests, monitoring the emergence of antifungal medication resistance, and research on the pathophysiology, prevention, and management of fungal infections are just a few potential solutions to these new health problems. The goal of this review is to summarize the data available for fungal infections and the different therapies which are involved in their treatment. Additionally, it also summarizes the molecular and scientific data of the plants which contain anti-fungal activity. Data are acquired using Google, PubMed, Scholar, and other online sources.

« Previous
Graphical Abstract

[1]
Reddy, G.K.K.; Padmavathi, A.R.; Nancharaiah, Y.V. Fungal infections: Pathogenesis, antifungals and alternate treatment approaches. Curr. Res. Microb. Sci., 2022, 3(3), 100137.
[http://dx.doi.org/10.1016/j.crmicr.2022.100137] [PMID: 35909631]
[2]
Perlroth, J.; Choi, B.; Spellberg, B. Nosocomial fungal infections: Epidemiology, diagnosis, and treatment. Med. Mycol., 2007, 45(4), 321-346.
[http://dx.doi.org/10.1080/13693780701218689] [PMID: 17510856]
[3]
Wilson, L.S.; Reyes, C.M.; Stolpman, M.; Speckman, J.; Allen, K.; Beney, J. The direct cost and incidence of systemic fungal infections. Value Health, 2002, 5(1), 26-34.
[http://dx.doi.org/10.1046/j.1524-4733.2002.51108.x] [PMID: 11873380]
[4]
Jarvis, W.R. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin. Infect. Dis., 1995, 20(6), 1526-1530.
[http://dx.doi.org/10.1093/clinids/20.6.1526] [PMID: 7548503]
[5]
Jarvis, W.R.; Martone, W.J. Predominant pathogens in hospital infections. J. Antimicrob. Chemother., 1992, 29(1), 19-24.
[http://dx.doi.org/10.1093/jac/29.suppl_A.19] [PMID: 1601752]
[6]
Nucci, M.; Pulcheri, W.; Spector, N.; Bueno, A.P.; Bacha, P.C.; Caiuby, M.J.; Derossi, A.; Costa, R.; Morals, J.C.; Oliveira, H.P. Fungal infections in neutropenic patients: A 8-year prospective study. Rev. Inst. Med. Trop. São Paulo, 1995, 37(5), 397-406.
[http://dx.doi.org/10.1590/S0036-46651995000500004] [PMID: 8729749]
[7]
Kanamaru, A.; Tatsumi, Y. Microbiological data for patients with febrile neutropenia. Clin. Infect. Dis., 2004, 39(S1), S7-S10.
[http://dx.doi.org/10.1086/383042] [PMID: 15250014]
[8]
Rees, J.R.; Pinner, R.W.; Hajjeh, R.A.; Brandt, M.E.; Reingold, A.L. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: Results of population-based laboratory active surveillance. Clin. Infect. Dis., 1998, 27(5), 1138-1147.
[http://dx.doi.org/10.1093/clinids/27.5.1138] [PMID: 9827260]
[9]
Wajszczuk, C.P.; Dummer, J.S.; Ho, M.; Van Thiel, D.H.; Starzl, T.; Iwatsuki, S.; Shaw, B., Jr Fungal infections in liver transplant recipients. Transplantation, 1985, 40(4), 347-353.
[http://dx.doi.org/10.1097/00007890-198510000-00002] [PMID: 3901440]
[10]
Baddley, J.W.; Stroud, T.P.; Salzman, D.; Pappas, P.G. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin. Infect. Dis., 2001, 32(9), 1319-1324.
[http://dx.doi.org/10.1086/319985] [PMID: 11303267]
[11]
Marr, K.A.; Carter, R.A.; Crippa, F.; Wald, A.; Corey, L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis., 2002, 34(7), 909-917.
[http://dx.doi.org/10.1086/339202] [PMID: 11880955]
[12]
Hibberd, P.L.; Rubin, R.H. Clinical aspects of fungal infection in organ transplant recipients. Clin. Infect. Dis., 1994, 19(S1), S33-S40.
[http://dx.doi.org/10.1093/clinids/19.Supplement_1.S33] [PMID: 7948569]
[13]
Haydour, Q.; Hage, C.A.; Carmona, E.M.; Epelbaum, O.; Evans, S.E.; Gabe, L.M.; Knox, K.S.; Kolls, J.K.; Wengenack, N.L.; Prokop, L.J.; Limper, A.H.; Murad, M.H. Diagnosis of fungal infections. A systematic review and meta-analysis supporting American Thoracic Society Practice Guideline. Ann. Am. Thorac. Soc., 2019, 16(9), 1179-1188.
[http://dx.doi.org/10.1513/AnnalsATS.201811-766OC] [PMID: 31219341]
[14]
Richardson, M.D.; Warnock, D.W. Fungal Infection: Diagnosis and management, 4th ed; John Wiley & Sons, 2012, pp. 1-7.
[http://dx.doi.org/10.1002/9781118321492]
[15]
Barlow, G.; Irving, W.L.; Moss, P.J. Infectious diseases.Kumar and Clark’s Clinical Medicine, 10th ed; Feather, A.; Randall, D.; Waterhouse, M., Eds.; Elsevier, 2020, pp. 559-563.
[16]
Vital Signs: Syphilis in Babies. 2019. www.cdc.gov (Assessed on: 04-Aug-2023).
[17]
Walsh, T.J.; Dixon, D.M. Spectrum of mycoses; Med Microbiol, 1996, pp. 919-925.
[18]
Bodey, G.P. , Ed.; Candidiasis, 2nd ed; Raven Press, 1992.
[19]
Dupont, B.; Denning, D.W.; Marriott, D.; Sugar, A.; Viviani, M.A.; Sirisanthana, T. Cutaneous Fungal Infections. In: Topics in Clinical Dermatology; , 1992.
[20]
Kwon-Chung, K.J.; Bennett, J.E. Infections due to miscellaneous molds. Med. Mycol. J., 1992, 733-767.
[21]
Matsumoto, T.; Ajello, L.; Matsuda, T.; Szaniszlo, P.J.; Walsh, T.J. Developments in hyalohyphomycosis and phaeohyphomycosis. Med. Mycol., 1994, 32(S1), 329-349.
[http://dx.doi.org/10.1080/02681219480000951] [PMID: 7722796]
[22]
Mcginnis, MR. Media and reagents.Laboratory handbook of medical mycology; , 1980.
[23]
Dupont, B.; Denning, D.W.; Marriott, D.; Sugar, A.; Viviani, M.A.; Sirisanthana, T. Mycoses in AIDS patients. Med. Mycol., 1994, 32(S1), 65-77.
[http://dx.doi.org/10.1080/02681219480000731] [PMID: 7722803]
[24]
Odds, F.C.; Arai, T.; Disalvo, A.F.; Evans, E.G.V.; Hay, R.J.; Randhawa, H.S.; Rinaldi, M.G.; Walsh, T.J. Nomenclature of fungal diseases: A report and recommendations from a sub-committee of the International Society for Human and Animal Mycology (ISHAM). Med. Mycol., 1992, 30(1), 1-10.
[http://dx.doi.org/10.1080/02681219280000021] [PMID: 1573518]
[25]
Odds, F.C. Candida and Candidosis. A Review and Bibliography, 2nd ed; Bailliere Tindall: Philadelphia, 1988.
[26]
Coccidioidomycosis, P.D. Semin. Dermatol., 1993, 301.
[27]
Mycology. In: Manual of clinical microbiology, 6th ed; Pfaller, M.A.; Fromtling, R.A., Eds.; Murray, PR; Baron, EJ; Pfaller, MA; Tenover, FC; Yolken, RH ASM Press: Washington, D.C, , 1995; pp. 697-855.
[28]
Tenover, R.H. Manual of Clinical Microbiology, 6th ed; American Society for Microbiology: Washington, D.C, 1994.
[29]
Rinaldi, M.G.; Dixon, D.M. The evolving etiologies of invasive mycoses. , Eds.; Infect Dis Clin Pract, 1994, 47.
[30]
Rippon, J.W. Medical mycology; the pathogenic fungi and the pathogenic actinomycetes; WB Saunders Company: Eastbourne, UK, 1982.
[31]
Sarosi, G.A.; Davies, S.F. Histoplasma capsulatum pneumonia. In: Respiratory infections: diagnosis and management; Pennington, J.E. , Ed.; , 1983; pp. 375-379.
[32]
Sternberg, S. The emerging fungal threat. Science, 1994, 266(5191), 1632-1634.
[http://dx.doi.org/10.1126/science.7702654] [PMID: 7702654]
[33]
Viviani, M.A.; Hill, J.O.; Dixon, D.M. Penicillium marneffei: Dimorphism and treatment. In: Dimorphic Fungi in Biology and Medicine; Vanden, B.H.; Odds, F.C.; Kerridge, D., Eds.; Springer: Boston, MA, 1993.
[http://dx.doi.org/10.1007/978-1-4615-2834-0_37]
[34]
Walsh, T.J.; de Pauw, B.; Anaissie, E.; Martino, P. Recent advances in the epidemiology, prevention and treatment of invasive fungal infections in neutropenic patients. Med. Mycol., 1994, 32(S1), 33-51.
[http://dx.doi.org/10.1080/02681219480000711] [PMID: 7722797]
[35]
Walsh, T.J.; Gonzalez, C.; Lyman, C.A.; Chanock, S.J.; Pizzo, P.A. Invasive fungal infections in children: Recent advances in diagnosis and treatment. Adv. Pediatr. Infect. Dis., 1996, 11(11), 187-290.
[PMID: 8718464]
[36]
Walsh, T.J.; Pizzo, P.A. Nosocomial fungal infections: A classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation. Annu. Rev. Microbiol., 1988, 42(1), 517-545.
[http://dx.doi.org/10.1146/annurev.mi.42.100188.002505] [PMID: 3060000]
[37]
Kutzner, H.; Kempf, W.; Feit, J.; Sangueza, O. 2. Fungal infections.In: Atlas of Clinical Dermatopathology; Infectious and Parasitic Dermatoses, 2021, pp. 77-108.
[38]
Nakazato, G.; Lonni, A.A.; Panagio, L.A.; de Camargo, L.C.; Gonçalves, M.C.; Reis, G.F.; Miranda-Sapla, M.M.; Tomiotto-Pellissier, F.; Kobayashi, R.K. Applications of nanometals in cutaneous infections.Nanotechnology in Skin, Soft Tissue, and Bone Infections; , 2020, pp. 71-92.
[39]
Stop neglecting fungi. Nat. Microbiol., 2017.
[40]
Kainz, K.; Bauer, M.A.; Madeo, F.; Carmona-Gutierrez, D. Fungal infections in humans: The silent crisis. Microb. Cell, 2020, 7(6), 143-145.
[http://dx.doi.org/10.15698/mic2020.06.718] [PMID: 32548176]
[41]
Sehgal, M.; Ladd, H.J.; Totapally, B. Trends in epidemiology and microbiology of severe sepsis and septic shock in children. Hosp. Pediatr., 2020, 10(12), 1021-1030.
[http://dx.doi.org/10.1542/hpeds.2020-0174] [PMID: 33208389]
[42]
Rodrigues, ML; Nosanchuk, JD Fungal diseases as neglected pathogens: A wake-up call to public health officials. PLoS Negl. Trop. Dis., 2021, 14(2), e0007964.
[43]
Li, Z.; Lu, G.; Meng, G. Pathogenic fungal infection in the lung. Front. Immunol., 2019, 10(10), 1524.
[http://dx.doi.org/10.3389/fimmu.2019.01524] [PMID: 31333658]
[44]
Fungal Infections (Mycosis). https://my.clevelandclinic.org/health/diseases/24401-fungal-infections-mycosis
[45]
Thrush in men. 2019. Available from: https://www.nidirect.gov.uk/conditions/thrush-men
[46]
Fungal Infections. 2003. Available from: https://en.wikipedia.org/wiki/Fungal_infection
[47]
Britt, LD; Peitzman, A.; Barie, P. Jurkovich, G Acute care surgery: What’s in a name? J. Trauma Acute Care Surg., 2012, 72(2), 319-320.
[http://dx.doi.org/10.1097/TA.0b013e31824b15c1]
[48]
Blyth, C.C.; Hale, K.; Palasanthiran, P.; O’Brien, T.; Bennett, M.H. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections; CDSR, 2010, p. 2.
[49]
Willinger, B. What is the target? clinical mycology and diagnostics.In: Clinically Relevant Mycoses; Springer, 2019, pp. 3-24.
[http://dx.doi.org/10.1007/978-3-319-92300-0_1]
[50]
Barnes, R.A. Early diagnosis of fungal infection in immunocompromised patients. J. Antimicrob. Chemother., 2008, 61(S1), i3-i6.
[http://dx.doi.org/10.1093/jac/dkm424] [PMID: 18063601]
[51]
Steinbach, W.J.; Mitchell, T.G.; Schell, W.A.; Espinel-ingroff, A.; Coico, R.F.; Walsh, T.J.J.; Perfect, J.R. Status of medical mycology education. Med. Mycol., 2003, 41(6), 457-467.
[http://dx.doi.org/10.1080/13693780310001631322] [PMID: 14725319]
[52]
Kozel, T.R.; Wickes, B. Fungal diagnostics. Cold Spring Harb. Perspect. Med., 2014, 4(4), a019299.
[http://dx.doi.org/10.1101/cshperspect.a019299] [PMID: 24692193]
[53]
Fungal Diseases and COVID-19. 2021. Available from: https://www.cdc.gov/fungal/covid-fungal.html
[54]
Segal, E.; Elad, D. Treatments for fungal infections. J. Fungi, 2018, 4(4), 135.
[http://dx.doi.org/10.3390/jof4040135] [PMID: 30545148]
[55]
McCarthy, M.; Katragkou, A.; Iosifidis, E.; Roilides, E.; Walsh, T. Recent advances in the treatment of scedosporiosis and fusariosis. J. Fungi, 2018, 4(2), 73.
[http://dx.doi.org/10.3390/jof4020073] [PMID: 29912161]
[56]
Sipsas, N.V.; Gamaletsou, M.N.; Anastasopoulou, A.; Kontoyiannis, D.P. Therapy of mucormycosis. J. Fungi, 2018, 4(3), 90.
[http://dx.doi.org/10.3390/jof4030090] [PMID: 30065232]
[57]
Jenks, J.; Hoenigl, M. Treatment of aspergillosis. J. Fungi, 2018, 4(3), 98.
[http://dx.doi.org/10.3390/jof4030098] [PMID: 30126229]
[58]
Brexafemme- ibrexafungerp tablet, film coated. 2021. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c33be3a1-c4fd-512c-e053-2995a90a63eb58
[59]
Ghosh, M. Fundamentals of experimental pharmacology. Indian J. Pharmacol., 2007.
[60]
Kaplan, G. Substance abuse in adolescents and young adults.In: A Manual for Pediatric and Primary Care Clinicians; De Gruyter, 2013.
[61]
MYCOSTATIN® Oral Drops. https://www.nps.org.au/assets/medicines/742a03eb-eb4b-4d44-a63a-a53300ff160f.pdf (Assessed on: 04-Aug-2023).
[62]
Relevant Billing Codes for AmBisome® (amphotericin B) liposome for injection. https://astellaspharmasupportsolutions.com/products/ambisome/ (Assessed on: 04-Aug-2023).
[63]
https://www.medlineindia.com/antibiotic-and-antiviral/griseofulvin.html (Assessed on: 04-Aug-2023).
[64]
Caspofungin https://go.drugbank.com/drugs/DB00520 (Assessed on: 04-Aug-2023).
[65]
Bertram, G.; Katzung, K.A. Basic & clinical pharmacology
[66]
Clark, M.A.; Harvey, R.A.; Finkel, R.; Rey, J.A.; Whalen, K. Eds.; Pharmacology; Lippincott Williams & Wilkins, 2011.
[67]
Shanbhag, TV; Shenoy, S Pharmacology for Medical Graduates-E-Book; Elsevier, 2022.
[68]
Laurence, L. Brunton, Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 13e Eds; McGraw Hill, 2017.
[69]
Udaykumar, P. Medical pharmacology. Indian J. Pharmacol., 2013.
[70]
Spectrazole Cream 20g. https://www.tnmeds.com/Skin-Care/prescription-drugs/Medicines/spectrazole-20g-15810.html (Assessed on: 04-Aug-2023).
[71]
Waller, DG; Sampson, A; Hitchings, A Medical pharmacology and therapeutics E-Book; Elsevier sci, 2021.
[72]
Hemmings, HC; Egan, TD Pharmacology and physiology for anesthesia e-book: Foundations and clinical application; Elsevier sci, 2012.
[73]
Shanbhag, TV; Shenoy, S. Pharmacology for Medical Graduates-E-Book; Elsevier, 2022.
[74]
Generic Oxistat Availability. https://www.drugs.com/availability/generic-oxistat.html (Assessed on: 04-Aug-2023).
[75]
Chisholm-Burns, MA; Terry, L.S.; Patrick, M.M.; Jill, M.K.; Bookstaver; Kelly, C.L. ., Eds.; Pharmacotherapy principles & practice; McGraw-Hill Education, 2016.
[76]
Testman, J.A. The prescribing cascade game: Applying geriatric pharmacotherapy principles in the classroom. Curr. Pharm. Teach. Learn., 2014, 6(5), 646-651.
[http://dx.doi.org/10.1016/j.cptl.2014.05.001]
[77]
Medical Information. https://www.pfizermedicalinformation.com/enus/diflucan (Assessed on: 04-Aug-2023).
[78]
https://www.rxlist.com/itraconazole/genericdrug (Assessed on: 04-Aug-2023). [Last ]
[79]
Goldstein, A.; Aronow, L.; Kalman, S.M. Principles of drug action. The basis of pharmacology. J. Med. Chem., 1970, 13(2), 337.
[http://dx.doi.org/10.1021/jm00296a900]
[80]
Neal, M.J. Medical pharmacology at a glance; John Wiley & Sons, 2020.
[81]
At Novartis, we are reimagining medicine. https://www.novartis.com (Assessed on: 04-Aug-2023).
[82]
Terbinafine. https://go.drugbank.com/drugs/Terbinafine (Assessed on: 04-Aug-2023).
[83]
undecylenicacid. https://www.rxlist.com/undecylenicacid (Assessed on: 04-Aug-2023).
[84]
Benzoic acid. https://go.drugbank.com/drugs/DB03793 (Assessed on: 04-Aug-2023).
[85]
Tripathi, K.D. Essentials of pharmacology for dentistry; Jaypee Brothers Medical Publishers, 2020, p. 23.
[86]
Scynexis Announces FDA Approval of Brexafemme. (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections; Scynexis, Inc, 2021.
[87]
Lamoth, F. Novel therapeutic approaches to invasive candidiasis: Considerations for the clinician. Infect. Drug Resist., 2023, 16, 1087-1097.
[http://dx.doi.org/10.2147/IDR.S375625] [PMID: 36855391]
[88]
Sobel, J.D.; Nyirjesy, P. Oteseconazole: An advance in treatment of recurrent vulvovaginal candidiasis. Future Microbiol., 2021, 16(18), 1453-1461.
[http://dx.doi.org/10.2217/fmb-2021-0173] [PMID: 34783586]
[89]
De, S.K. Oteseconazole: First approved orally bioavailable and selective CYP51 inhibitor for the treatment of patients with recurrent vulvovaginal candidiasis. Curr. Med. Chem., 2023, 30(37), 4170-4175.
[http://dx.doi.org/10.2174/0929867330666230220130024] [PMID: 36803759]
[90]
Wright, C.R.; Ward, A.C.; Russell, A.P. Granulocyte colony-stimulating factor and its potential application for skeletal muscle repair and regeneration. Mediators Inflamm., 2017, 2017, 1-9.
[http://dx.doi.org/10.1155/2017/7517350] [PMID: 29362521]
[91]
Costa, J.J. The therapeutic use of hematopoietic growth factors. J. Allergy Clin. Immunol., 1998, 101(1), 1-6.
[http://dx.doi.org/10.1016/S0091-6749(98)70185-X] [PMID: 9449493]
[92]
Rowe, J.M. Concurrent use of growth factors and chemotherapy in acute leukemia. Curr. Opin. Hematol., 2000, 7(3), 197-202.
[http://dx.doi.org/10.1097/00062752-200005000-00012] [PMID: 10786659]
[93]
Safdar, A.; Rodriguez, G.; Zuniga, J.; Al Akhrass, F.; Georgescu, G.; Pande, A. Granulocyte macrophage colony-stimulating factor in 66 patients with myeloid or lymphoid neoplasms and recipients of hematopoietic stem cell transplantation with invasive fungal disease. Acta Haematol., 2013, 129(1), 26-34.
[http://dx.doi.org/10.1159/000342121] [PMID: 23038157]
[94]
Vanitha, S.; Chaubey, N.; Ghosh, S.S.; Sanpui, P. Recombinant human granulocyte macrophage colony stimulating factor (hGM-CSF): Possibility of nanoparticle-mediated delivery in cancer immunotherapy. Bioengineered, 2017, 8(2), 120-123.
[http://dx.doi.org/10.1080/21655979.2016.1212136] [PMID: 27459024]
[95]
Stevens, D.A.; Brummer, E.; Clemons, K.V. Interferon-γ as an antifungal. J. Infect. Dis., 2006, 194(S1), S33-S37.
[http://dx.doi.org/10.1086/505357] [PMID: 16921470]
[96]
Wang, H.; Asavaroengchai, W.; Yong Yeap, B.; Wang, M.G.; Wang, S.; Sykes, M.; Yang, Y.G. Paradoxical effects of IFN-γ in graft-versus-host disease reflect promotion of lymphohematopoietic graft-versus-host reactions and inhibition of epithelial tissue injury. Blood, 2009, 113(15), 3612-3619.
[http://dx.doi.org/10.1182/blood-2008-07-168419] [PMID: 19211507]
[97]
Kandalla, P.K.; Sarrazin, S.; Molawi, K.; Berruyer, C.; Redelberger, D.; Favel, A.; Bordi, C.; de Bentzmann, S.; Sieweke, M.H. M-CSF improves protection against bacterial and fungal infections after hematopoietic stem/progenitor cell transplantation. J. Exp. Med., 2016, 213(11), 2269-2279.
[http://dx.doi.org/10.1084/jem.20151975] [PMID: 27811055]
[98]
Medina-Echeverz, J.; Aranda, F.; Berraondo, P. Myeloid-derived cells are key targets of tumor immunotherapy. OncoImmunology, 2014, 3(4), e28398.
[http://dx.doi.org/10.4161/onci.28398] [PMID: 25050208]
[99]
Schneider, A.; Blatzer, M.; Posch, W.; Schubert, R.; Lass-Flörl, C.; Schmidt, S.; Lehrnbecher, T. Aspergillus fumigatus responds to natural killer (NK) cells with upregulation of stress related genes and inhibits the immunoregulatory function of NK cells. Oncotarget, 2016, 7(44), 71062-71071.
[http://dx.doi.org/10.18632/oncotarget.12616] [PMID: 27738337]
[100]
Davies, J.O.J.; Stringaris, K.; Barrett, A.J.; Rezvani, K. Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease. Cytotherapy, 2014, 16(11), 1453-1466.
[http://dx.doi.org/10.1016/j.jcyt.2014.03.009] [PMID: 24856895]
[101]
Casadevall, A.; Dadachova, E.; Pirofski, L. Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol., 2004, 2(9), 695-703.
[http://dx.doi.org/10.1038/nrmicro974] [PMID: 15372080]
[102]
Cassone, A. Fungal vaccines: Real progress from real challenges. Lancet Infect. Dis., 2008, 8(2), 114-124.
[http://dx.doi.org/10.1016/S1473-3099(08)70016-1] [PMID: 18222162]
[103]
Chames, P.; Van Regenmortel, M.; Weiss, E.; Baty, D. Therapeutic antibodies: Successes, limitations and hopes for the future. Br. J. Pharmacol., 2009, 157(2), 220-233.
[http://dx.doi.org/10.1111/j.1476-5381.2009.00190.x] [PMID: 19459844]
[104]
Rajasekharan, S.K.; Lee, J.H.; Lee, J. Aripiprazole repurposed as an inhibitor of biofilm formation and sterol biosynthesis in multidrug-resistant Candida albicans. Int. J. Antimicrob. Agents, 2019, 54(4), 518-523.
[http://dx.doi.org/10.1016/j.ijantimicag.2019.05.016] [PMID: 31173863]
[105]
Capoci, I.R.G.; Faria, D.R.; Sakita, K.M.; Rodrigues-Vendramini, F.A.V.; Bonfim-Mendonça, P.S.; Becker, T.C.A.; Kioshima, É.S.; Svidzinski, T.I.E.; Maigret, B. Repurposing approach identifies new treatment options for invasive fungal disease. Bioorg. Chem., 2019, 84(1), 87-97.
[http://dx.doi.org/10.1016/j.bioorg.2018.11.019] [PMID: 30496872]
[106]
Spitzer, M.; Griffiths, E.; Blakely, K.M.; Wildenhain, J.; Ejim, L.; Rossi, L.; De Pascale, G.; Curak, J.; Brown, E.; Tyers, M.; Wright, G.D. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol. Syst. Biol., 2011, 7(1), 499.
[http://dx.doi.org/10.1038/msb.2011.31] [PMID: 21694716]
[107]
Harrison, T.S.; Griffin, G.E.; Levitz, S.M. Conditional lethality of the diprotic weak bases chloroquine and quinacrine against Cryptococcus neoformans. J. Infect. Dis., 2000, 182(1), 283-289.
[http://dx.doi.org/10.1086/315649] [PMID: 10882608]
[108]
Kulkarny, V.V.; Chavez-Dozal, A.; Rane, H.S.; Jahng, M.; Bernardo, S.M.; Parra, K.J.; Lee, S.A. Quinacrine inhibits Candida albicans growth and filamentation at neutral pH. Antimicrob. Agents Chemother., 2014, 58(12), 7501-7509.
[http://dx.doi.org/10.1128/AAC.03083-14] [PMID: 25288082]
[109]
Garcia, C.; Burgain, A.; Chaillot, J.; Pic, É.; Khemiri, I.; Sellam, A. A phenotypic small-molecule screen identifies halogenated salicylanilides as inhibitors of fungal morphogenesis, biofilm formation and host cell invasion. Sci. Rep., 2018, 8(1), 11559.
[http://dx.doi.org/10.1038/s41598-018-29973-8] [PMID: 30068935]
[110]
Dehdashti, S.J.; Abbott, J.; Nguyen, D.T.; McKew, J.C.; Williamson, P.R.; Zheng, W. A high-throughput screening assay for assessing the viability of Cryptococcus neoformans under nutrient starvation conditions. Anal. Bioanal. Chem., 2013, 405(21), 6823-6829.
[http://dx.doi.org/10.1007/s00216-013-7134-4] [PMID: 23812880]
[111]
Mei, Y.; Jiang, T.; Zou, Y.; Wang, Y.; Zhou, J.; Li, J.; Liu, L.; Tan, J.; Wei, L.; Li, J.; Dai, H.; Peng, Y.; Zhang, L.; Lopez-Ribot, J.L.; Shapiro, R.S.; Chen, C.; Liu, N.N.; Wang, H. FDA approved drug library screening identifies robenidine as a repositionable antifungal. Front. Microbiol., 2020, 11(11), 996.
[http://dx.doi.org/10.3389/fmicb.2020.00996] [PMID: 32582050]
[112]
Spitzer, M.; Robbins, N.; Wright, G.D. Combinatorial strategies for combating invasive fungal infections. Virulence, 2017, 8(2), 169-185.
[http://dx.doi.org/10.1080/21505594.2016.1196300] [PMID: 27268286]
[113]
Vitale, R.G. Role of antifungal combinations in difficult to treat Candida infections. J. Fungi, 2021, 7(9), 731.
[http://dx.doi.org/10.3390/jof7090731] [PMID: 34575770]
[114]
Mourad, A.; Perfect, J. Present and future therapy of Cryptococcus infections. J. Fungi, 2018, 4(3), 79.
[http://dx.doi.org/10.3390/jof4030079] [PMID: 29970809]
[115]
Ferreira, M.R.A.; Santiago, R.R.; Langassner, S.M.Z.; Palazzo de Mello, J.C.; Svidzinski, T.I.E.; Soares, L.A.L. Antifungal activity of medicinal plants from Northeastern Brazil. J. Med. Plants Res., 2013, 7(40), 3008-3013.
[http://dx.doi.org/10.5897/JMPR2013.5035]
[116]
Mishra, K.K.; Kaur, C.D.; Sahu, A.K.; Panik, R.; Kashyap, P.; Mishra, S.P.; Dutta, S. Medicinal plants having antifungal properties.Medicinal Plants-Use in Prevention and Treatment of Diseases; , 2020.
[117]
Koroishi, A.M.; Foss, S.R.; Cortez, D.A.G.; Ueda-Nakamura, T.; Nakamura, C.V.; Dias Filho, B.P. In vitro antifungal activity of extracts and neolignans from Piper regnellii against dermatophytes. J. Ethnopharmacol., 2008, 117(2), 270-277.
[http://dx.doi.org/10.1016/j.jep.2008.01.039] [PMID: 18394835]
[118]
Manojlovic, N.T.; Solujic, S.; Sukdolak, S.; Milosev, M. Antifungal activity of Rubia tinctorum, Rhamnus frangula and Caloplaca cerina. Fitoterapia, 2005, 76(2), 244-246.
[http://dx.doi.org/10.1016/j.fitote.2004.12.002] [PMID: 15752641]
[119]
Yemele Bouberte, M.; Krohn, K.; Hussain, H.; Dongo, E.; Schulz, B.; Hu, Q. Tithoniamarin and tithoniamide: a structurally unique isocoumarin dimer and a new ceramide fromTithonia diversifolia. Nat. Prod. Res., 2006, 20(9), 842-849.
[http://dx.doi.org/10.1080/14786410500462892] [PMID: 16753922]
[120]
Portillo, A.; Vila, R.; Freixa, B.; Adzet, T.; Cañigueral, S. Antifungal activity of Paraguayan plants used in traditional medicine. J. Ethnopharmacol., 2001, 76(1), 93-98.
[http://dx.doi.org/10.1016/S0378-8741(01)00214-8] [PMID: 11378288]
[121]
Endo, K.; Kanno, E.; Oshima, Y. Structures of antifungal diarylheptenones, gingerenones A, B, C and isogingerenone B, isolated from the rhizomes of Zingiber officinale. Phytochemistry, 1990, 29(3), 797-799.
[http://dx.doi.org/10.1016/0031-9422(90)80021-8]
[122]
Dabur, R.; Diwedi, S.K.; Yadav, V.; Mishra, V.; Singh, R.; Singh, H.; Sharma, G.L. Efficacy of 2-(3,4-dimethyl-2,5-dihydro-1h-pyrrole-2-yl)-1-methylethyl pentanoate in a murine model of invasive aspergillosis. Antimicrob. Agents Chemother., 2005, 49(10), 4365-4367.
[http://dx.doi.org/10.1128/AAC.49.10.4365-4367.2005] [PMID: 16189123]
[123]
Ingham, J.L.; Tahara, S.; Harborne, J.B. Fungitoxic isoflavones from Lupinus albus and other Lupinus species. Z. Naturforsch. C J. Biosci., 1983, 38(3-4), 194-200.
[http://dx.doi.org/10.1515/znc-1983-3-407]
[124]
Bar-Nun, N.; Mayer, A.M. Cucurbitacins protect cucumber tissue against infection by Botrytis cinerea. Phytochemistry, 1990, 29(3), 787-791.
[http://dx.doi.org/10.1016/0031-9422(90)80019-D]
[125]
Kim, K.Y.; Davidson, P.M.; Chung, H.J. Antibacterial activity in extracts of Camellia japonica L. petals and its application to a model food system. J. Food Prot., 2001, 64(8), 1255-1260.
[http://dx.doi.org/10.4315/0362-028X-64.8.1255] [PMID: 11510672]
[126]
Kobayashi, K.; Nishino, C.; Tomita, H.; Fukushima, M. Antifungal activity of pisiferic acid derivatives against the rice blast fungus. Phytochemistry, 1987, 26(12), 3175-3179.
[http://dx.doi.org/10.1016/S0031-9422(00)82465-6]
[127]
Ito, T.; Kumazawa, K. Antifungal substances from mechanically damaged cherry leaves (Prumus yedoensis matsumura). Biosci. Biotechnol. Biochem., 1992, 56(10), 1655.
[http://dx.doi.org/10.1271/bbb.56.1655]
[128]
Agrawal, K.; Pathak, D.; Kulshreshtha, M. Pharmacognostical, Phytochemical, and Pharmacological Aspects of Aegle marmelos: An Update. Current Functional Foods, 2023, p. 01.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy